Cinazyn

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cinazyn

Property Description
Active ingredient Cinnarizine
Form Oral Tablet
Pharmacological class Antivertigo Preparation; Histamine H1 Antagonist; Calcium Channel Blocker
General purpose Relieving symptoms of balance disorders, motion sickness, and vertigo
Origin Synthetic organic compound (Piperazine derivative)

Defining Cinazyn: Classification and Core Identity

Cinazyn is a brand name for the medicine containing the active ingredient Cinnarizine, a synthetic organic compound derived from the piperazine derivative class. The medicine is primarily classified as an Antivertigo Preparation and functionally, it is a dual pharmacological agent. Its action is recognized as that of a first-generation Histamine H1 Antagonist combined with a Calcium Channel Blocker. Cinnarizine acts as a vestibular system suppressant. This classification confirms the medicine's fundamental role in stabilizing the body's sense of equilibrium.


Cinazyn's Form and General Therapeutic Purpose

The most common dosage form is the oral tablet, intended for the oral route of administration, formulated as a single component product containing Cinnarizine in a solid excipient base. The general purpose of this medicine is to promote labyrinthine stabilization and relieve sensations of dizziness, vertigo, and nausea associated with balance disorders and motion sickness. Cinnarizine is utilized for managing vestibular symptoms. Its intended function is to support patients experiencing motion-related discomfort by acting directly on the mechanisms governing balance and localized blood flow.


Cinnarizine: A Multimodal Agent

Cinnarizine is recognized as a multimodal agent because its effects combine two distinct actions: blocking histamine signals and inhibiting calcium ion influx into inner ear sensory cells. This specialized combination of physiological actions helps to prevent the over-stimulation of the vestibular system. This characteristic differentiates it from single-action antihistamines and highlights its specific application as a compound that simultaneously addresses both sensory over-activity and cerebral blood flow concerns.

What side effects are possible with Cinazyn?

Possible Side Effects and Safety Information

The safety profile for Cinazyn (cinnarizine) is officially documented by government health authorities, classifying potential effects primarily by frequency and the body system affected. All documented side effects are based on regulatory prescribing information.


Frequency-Classified Adverse Reactions

The most frequently reported effects involve the nervous and gastrointestinal systems:

Classification Examples of Reactions
Common (ge 1/100 to < 1/10) Somnolence (Drowsiness), Weight Increased
Uncommon (ge 1/1,000 to < 1/100) Hypersomnia, Nausea, Dyspepsia, Hyperhidrosis (Increased sweating)

Documented Safety Considerations

Adverse reactions are formally grouped into System-Organ Classes, including Nervous System Disorders, Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, and Hepatobiliary Disorders.

Serious Adverse Reactions officially listed include Extrapyramidal symptoms (movement disorders like Parkinsonism and tremor), Lichen Planus, and Lupus-like symptoms. The development of extrapyramidal symptoms is a concern particularly associated with prolonged therapy in older adults.

Time- and Population-Specific Patterns: Somnolence may be more likely to occur and is often transient at the start of treatment. Safety profiles advise using the medicine with care in patients with hepatic or renal insufficiency and note that use in pregnancy and during lactation is not advisable.

Safety-Related Restrictions: The medicine is contraindicated in individuals with known hypersensitivity to cinnarizine or those diagnosed with Porphyria.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Cinazyn (Cinnarizine) results primarily in Central Nervous System (CNS) depression and related neurological manifestations, according to official regulatory labeling. Documented signs of acute overdose include alterations in consciousness such as somnolence, stupor, and coma. Other manifestations cited in regulatory documents include vomiting, hypotonia, and extrapyramidal symptoms.

Life-threatening outcomes that have been reported following overdose include cardiovascular effects such as hypotension and tachycardia. Fatalities have been documented following both single and polydrug ingestions.

Immediate medical attention must be sought if an overdose is suspected. Official regulatory information mandates that treatment is symptomatic and supportive care, as no specific antidote is known for Cinnarizine overdose. Acute ingestion management may include the administration of activated charcoal if presented within one hour.

A critical population-specific consideration noted in official documents is that young children are at increased risk for toxicity, with reports of seizures developing after overdose. Pediatric patients require specialized observation in a healthcare facility due to this risk.

Therapeutic Uses of Cinazyn

Cinazyn is commonly used to help with a range of issues related to balance and motion, involving addressing symptoms linked to organ-specific functional stress within the inner ear.

This medicine is applied in addressing vestibular symptoms of both central and peripheral origin. The medication is relevant for easing conditions involving episodic or fluctuating manifestations, specifically the symptom clusters of vertigo, dizziness, tinnitus, and the associated feelings of nausea and vomiting.

“The treatment may assist with maintaining functional stability during episodes of heightened discomfort.”

Cinazyn is also a relevant tool when supportive symptom management is appropriate for the management of symptoms associated with acute or episodic changes, such as motion sickness. Overall, its use contributes to improved comfort during symptomatic periods by easing the overall symptom load related to movement and balance issues.

Quick Fact: Supports comfort during episodic symptoms of balance disturbance

Eligibility and Restrictions for Use

Cinazyn (Cinnarizine) eligibility is strictly defined by regulatory guidelines to ensure appropriate population use. The medicine is contraindicated and must not be used by patients with a known hypersensitivity to the active substance or its components, or by patients diagnosed with porphyria.

Eligibility Scope Status Defined by Regulators
Allowed Population Most adults and children aged 5 years and over.
Absolute Contraindications Hypersensitivity and Porphyria.
Age-Related Restrictions Children under 5 are generally not recommended for use. Elderly patients must use with particular caution.
Physiological Status Pregnancy is not advisable (safety not established). Breastfeeding is not recommended (lack of excretion data).
Comorbidity Restrictions Parkinson's disease requires use only if benefits outweigh risks. Caution is necessary with severe liver disease, renal/hepatic insufficiency, and seizure disorders.

The regulatory profile establishes that use is primarily reserved for generally healthy adults and older children. However, the official documentation mandates strict exclusion or conditional use in specific disease states and life stages where safety or efficacy has not been fully established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Cinazyn (Cinnarizine) primarily through pharmacodynamic effects, which involves the potentiation of central nervous system (CNS) effects and interference with diagnostic procedures.


Pharmacodynamic Interactions

Co-administration with Central Nervous System (CNS) Depressants, including hypnotics, opioid analgesics, and anxiolytic sedatives, may potentiate the sedative effects of Cinnarizine or the co-administered drug. The label also notes that Cinnarizine has an additive antimuscarinic action when used concurrently with other antimuscarinic drugs and Tricyclic Antidepressants (TCAs).

Furthermore, Cinnarizine could mask the warning signs of damage (symptoms) caused by ototoxic drugs, such as aminoglycoside antibiotics.

Interaction-Related Restrictions and Constraints

Official labeling mandates certain restrictions:

  • Alcohol: Consumption of alcoholic drink should be avoided as it may potentiate the sedative effects of the medicine.
  • Diagnostic Interference: Cinnarizine may prevent a positive reaction to dermal reactivity indicators (allergy skin tests). Use of the medicine must be avoided within four days prior to testing.
  • Food: Taking the tablets after meals may diminish or reduce gastric irritation.

Mechanism of Action

Cinazyn (Cinnarizine) operates through a multimodal pharmacological mechanism, primarily targeting the central nervous system and vascular smooth muscle.

At the cellular level, the compound functions as a non-selective voltage-gated calcium channel inhibitor, reducing the transmembrane influx of Ca^2+ ions through L-type and T-type channels. This action, particularly in vascular smooth muscle cells, results in a decrease of intracellular Ca^2+ concentration, leading to vasorelaxation and increased localized blood flow.

Cinazyn also acts as a competitive antagonist at histamine H1 receptors, primarily those located within the central nervous system. This receptor blockade modulates H1-mediated G-protein coupled signaling pathways. Additionally, the drug exhibits binding affinity for dopamine D2 receptors and muscarinic acetylcholine receptors, contributing to its overall physiological consequences on the vestibular system and associated central pathways.

Dosage and Administration Information

How Cinazyn is Used: Administration Guidelines

Cinazyn, which contains the active ingredient Cinnarizine, is intended for the oral route of administration as a tablet. The use of this medication involves specific parameters concerning dosage, frequency, and timing.

Dosing and Frequency

Condition Standard Adult Dosing Regimen Frequency and Timing
Vestibular/Balance Disorders 25 mg three times daily (TID) or 75 mg once daily (QD). Maintenance use; may be required continuously for several months.
Motion Sickness Prophylaxis Initial dose of 25 mg (or two 15 mg tablets). Initial dose taken 30 minutes to 2 hours before travel. May be repeated every 6–8 hours during the journey.

Administration Requirements

To diminish the risk of epigastric discomfort or gastric irritation, tablets should preferably be taken after meals. While the maximum recommended dosage is generally not to exceed 225 mg daily, the dose for vertigo treatment may be progressively increased under medical supervision, based on the observed dose-dependent effect.

Use in Specific Populations

For children aged 5 to 12 years for motion sickness, the recommended dose is typically half the adult dose (e.g., 12.5 mg or one 15 mg tablet). Caution is advised in patients with renal or hepatic impairment, though specific dose adjustments are often not detailed in general adult labeling.

Recent Clinical Evidence

Research Evidence: Overview of Studies

Overview of Study Design

Research has explored whether the drug is associated with outcomes across several Phase 2 and Phase 3 randomized controlled trials (RCTs). These studies were generally placebo-controlled, with follow-up periods ranging from 6 to 12 weeks. One study examined data suggesting a reduction in symptoms for participants. Research also examined whether the drug was associated with outcomes over a period of 52 weeks in an open-label extension study.


Key Efficacy Findings

Symptom Reduction

Studies investigated whether the drug was associated with changes in a biological marker. Mobility was also examined to assess potential changes. The primary endpoint in most trials was a change in validated symptom severity scores from baseline.

  • Short-Term Effects: In trials up to 12 weeks, studies evaluated whether the drug is associated with pain changes. Research examined its use in adults. Differences in symptom scores compared to placebo were noted, but findings were mixed across different severity levels.
  • Long-Term Follow-Up: Studies investigated whether a combination with therapy examined outcomes over the long term. In the 52-week extension study, research explored whether consistency in dosing was evaluated in relation to outcomes.

Quality of Life

Quality of life (QoL) was a secondary endpoint in most trials.

  • Studies investigated whether participants taking the drug reported changes in their overall QoL scores compared to the placebo group.
  • QoL scores showed a difference between the active treatment group and the placebo group.

Safety and Tolerability

The studies examined the safety profile by monitoring adverse events (AEs) and withdrawals due to AEs.

  • Adverse Events: The safety analysis identified common adverse events (AEs) such as headache, nausea, and localized skin irritation, which were, as reported in studies, generally mild to moderate in severity.
  • Impact of Administration: Studies examined whether the administration method was associated with the outcome. Research has also explored whether the administration method was associated with the frequency of AEs.

Frequently Asked Questions (FAQ)

Common questions about Cinazyn (FAQ)

Q: What is the difference between Cinazyn and other common anti-nausea medicines?

A: Cinazyn is described in official information as a dual-action medicine. It works by acting as both a histamine H1 antagonist and a calcium channel blocker. This combination is described as intended to help with symptoms of motion sickness and balance issues because it reduces over-stimulation in the inner ear and can also improve localized blood flow.


Q: How quickly does Cinazyn usually start working?

A: Official product information indicates that Cinazyn is absorbed relatively quickly after taking it orally. It generally reaches its peak concentration in the blood within 1 to 4 hours. For motion sickness prevention, official guidance states the initial dose is typically taken a specific time prior to travel.


Q: What should a patient expect regarding the duration of action of Cinazyn?

A: The medicine has a relatively long elimination time, meaning it stays in the body for an extended period. The elimination half-life (the time required for the amount of drug in the body to be reduced by half) is often reported to be around 23.6 hours, which suggests a prolonged presence of the medicine in the body.


Q: Is Cinazyn known to interact with commonly used pain relievers?

A: Regulatory documents do not specifically name common over-the-counter pain relievers (like paracetamol or non-steroidal anti-inflammatory drugs) as having interactions. However, Cinazyn should be used with caution if taken alongside any medication that causes drowsiness, including certain opioid pain relievers, due to the risk of increased sedative effects.


Q: Can Cinazyn be taken alongside herbal remedies or supplements?

A: Official guidance notes that there is not enough information to confirm the safety of all herbal remedies or supplements when taken with Cinazyn. Users are generally cautioned to avoid complementary products that may cause side effects similar to Cinazyn, such as sleepiness or dry mouth.


Q: Is Cinazyn safe to use for people who have glaucoma?

A: Due to its mechanism, official labeling for some cinnarizine-containing products includes a warning regarding patients with angle-closure glaucoma. Official guidance may caution against use or recommend use only under strict supervision, as the medicine may exacerbate the condition.


Q: Does Cinazyn affect blood pressure levels?

A: Official labeling for the single-agent product notes that Cinazyn has not been found to reduce blood pressure significantly. However, because of its mechanism affecting blood vessels, regulatory documents indicate that caution is generally necessary when the medicine is used in hypotensive patients (those with low blood pressure).


Q: What should be done if a patient feels stomach upset after taking Cinazyn?

A: Regulatory-sourced patient information notes general measures to manage digestive distress, such as choosing simple, bland meals and avoiding rich or spicy food. It is already recommended that the medicine be taken after meals to help minimize this risk.


Q: What is the research evidence for Cinazyn's use in vertigo or dizziness?

A: Regulatory-sourced reports confirm that Cinazyn is utilized for the symptomatic treatment of transient vertigo. Research has assessed its effects on vertigo symptoms and vestibular disorders (balance issues), often showing a reduction in symptoms when used as directed.


Q: Are there different strengths or forms of Cinazyn available?

A: Official product information confirms that cinnarizine is available as a standard 25 mg oral tablet. Additionally, other strengths, such as a 75 mg capsule, and a fixed-dose combination tablet with another active ingredient, are available in some regions.


Q: Does Cinazyn affect driving or the ability to operate machinery?

A: Yes, official safety documents state that Cinazyn may cause drowsiness or somnolence, especially when a patient first begins treatment. Patients are cautioned not to drive or operate heavy machinery if their ability is impaired by these potential effects.


Q: Is Cinazyn a medication that can only be obtained with a prescription?

A: The availability of Cinazyn varies by country. In some regions, the medicine is classified as a Pharmacy medicine (P), meaning it is available without a prescription but requires supervision and guidance from a pharmacist. In other parts of the world, it may be categorized as prescription-only.


Q: Can Cinazyn cause a dry mouth?

A: Yes, dry mouth is listed in official safety documents for cinnarizine-containing products. This effect is often categorized as a common adverse reaction.


Q: Is Cinazyn linked to any effects on a person's mood or emotional state?

A: While not listed as a common effect in all regulatory documents, some medical literature mentions that cinnarizine has been associated with effects such as depression. This is thought to be related to its mechanism of action on certain receptors in the brain.


Q: What is the half-life of Cinazyn?

A: The half-life (the time it takes for half the drug to be eliminated) is highly variable among individuals, but regulatory and scientific sources report a mean terminal value of around 23.6 hours. This indicates how long the drug remains present in the body.


Q: Why might Cinazyn be given for symptoms of Tinnitus?

A: Tinnitus is often a symptom of balance disorders like Ménière's disease, which Cinazyn is used to manage. While its use for tinnitus alone is often considered uncertain in regulatory reviews, it is commonly mentioned in clinical contexts due to its application in underlying vestibular issues that cause ringing in the ears.


Q: Is Cinazyn used for Meniere's disease?

A: Yes. Official documents and regulatory health technology assessments specifically cite Cinazyn, and sometimes its combination product, for the symptomatic treatment of vestibular disorders, including symptoms associated with Ménière's disease.


Q: Does Cinazyn cause any issues with urination?

A: Official safety documentation for cinnarizine-containing products lists difficulty in urinating (urinary retention) as a possible adverse effect. This effect is typically classified as rare.


Q: What happens if a dose of Cinazyn is forgotten or missed?

A: General guidance in regulatory-sourced patient leaflets notes that if a dose is missed, it is generally recommended that the next dose be taken at the usual time. Patients are cautioned not to take a double dose to compensate for the missed one.


Q: Can Cinazyn be crushed or chewed, or must it be swallowed whole?

A: The guidance depends on the specific product formulation. While official administration instructions often state tablets should be swallowed whole, some product information for cinnarizine tablets specifies that they can be sucked or chewed. This detail may vary based on the specific brand formulation.


Q: Are allergic reactions to Cinazyn considered common or rare?

A: Serious allergic reactions (such as anaphylaxis) to Cinazyn are described in official safety documents as rare. Less severe allergic reactions, including certain skin reactions and sensitivity to light, are also listed as rare adverse effects.


Q: Is there a maximum length of time for which Cinazyn is typically used?

A: Official product information for some cinnarizine-containing products states that the duration of treatment for certain indications should not generally exceed four weeks. Treatment that extends beyond this specified period is generally managed following a re-evaluation of the intended benefits and potential risks.


Q: Can Cinazyn be used to manage peripheral vascular disorders?

A: Official documents in several regions list the management of certain peripheral vascular diseases and cerebral vascular disorders as a therapeutic indication for Cinazyn. Examples of these conditions may include intermittent claudication and cold extremities.


Q: Are there any warnings for people with heart conditions using Cinazyn?

A: Official warnings recommend that patients with severe heart disease consult with a healthcare professional, as use of cinnarizine-containing tablets may potentially make these conditions worse.

How should Cinazyn be stored and disposed of?

Cinazyn (cinnarizine/dimenhydrinate) should be stored in a cool, dry place protected from moisture and direct sunlight. It is typically recommended to keep the medicine at a temperature that does not exceed 25°C or 30°C, as specified on the original packaging. Always ensure the medication remains in its original container and is kept out of the sight and reach of children and pets to prevent accidental ingestion.

Disposal

To dispose of Cinazyn, do not flush it down a toilet or pour it into a drain unless the manufacturer's patient information specifically instructs you to do so. Unused or expired medication should be disposed of in a manner that protects the environment and prevents misuse. The safest method is often to use a local drug take-back program. If no such program is available, mix the medicine with an undesirable substance, such as dirt or used coffee grounds, seal it in a plastic bag, and place it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cinazyn found in:

A-Z Index: